Drug Development
Debiopharm presents new data confirming anti-HCV activity of cyclophilin inhibitor Debio-025
Published in Hepatitis Weekly, November 27th, 2006
The aim of the study was to determine the anti-viral effect, pharmacokinetic profile and safety of an oral therapy with Debio-025. The data, presented at the American Association for the Study of Liver Diseases (AASLD) conference, confirm the anti-viral effect of Debio-025 in HIV/HCV co-infected subjects.
The 15 day double-blind, placebo-controlled study, with twice daily...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-11-27)
More Articles from Hepatitis Weekly
- Hepatitis A Virus
Researchers at Afyon Kocatepe University release new data on hepatitis a virus in children - Hepatitis B Virus Therapy
Studies from Health Science Center, Department of Biochemistry and Molecular Biology further understanding of hepatitis b virus therapy - Hepatitis B Virus Vaccines
Reports outline hepatitis b virus vaccines research from Tor Vergata University, Department of Public Health - Hepatitis C Virus
Findings from Scripps Research Institute, Department of Molecular and Experimental Medicine provide new insights into hepatitis c virus - Hepatitis C Virus
Reports outline hepatitis c virus study findings from Osaka University, Department of Molecular Virology - Hepatitis C Virus Cell Biology
Investigators at Scripps Research Institute target hepatitis c virus cell biology - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
